Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children's Cancer Group.
机构：[1]Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China,[2]National Children’s Medical Center, Department of Hematology/Oncology, Key Laboratory of Pediatric Hematology and Oncology of China Ministry of Health, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China,首都医科大学附属北京儿童医院[3]State Key Laboratory of Experimental Hematology and Division of Pediatric Blood Diseases Center, Institute of Hematology and Blood Diseases Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Tianjin, China,[4]Department of Hematology/Oncology, Children’s Hospital of Soochow University, Suzhou, China,[5]Department of Pediatrics, Key Laboratory of Birth Defects and Related Disease of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China,[6]Department of Hematology/Oncology, Guangzhou Women and Children’s Medical Center, Guangzhou, China,[7]Department of Hematology/Oncology, Children’s Hospital of Fudan University, Shanghai, China,[8]Department of Hematology/Oncology, Kunming Children’s Hospital, Kunming, China,[9]Department of Hematology/ Oncology, Children’s Hospital of Nanjing Medical University, Nanjing, China,[10]Department of Pediatrics, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,华中科技大学同济医学院附属协和医院[11]Department of Pediatrics, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China,华中科技大学同济医学院附属同济医院[12]Department of Hematology/Oncology, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, China,[13]Department of Pediatrics, Anhui Medical University Second Affiliated Hospital, Hefei, China,[14]Department of Pediatrics, Affiliated Hospital of Qingdao University, Qingdao, China,[15]Department of Pediatrics, Hong Kong Children’s Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China,[16]Department of Pediatrics, Xiangya Hospital Central South University, Changsha, China,[17]Department of Hematology/Oncology, Xi’an Northwest Women and Children Hospital, Xi’an, China,[18]Department of Pediatrics, Nanfang Hospital, Southern Medical University, Guangzhou, China,[19]Department of Hematology/ Oncology, Jiangxi Provincial Children’s Hospital, Nanchang, China,[20]Department of Hematology/Oncology, Chongqing Medical University Affiliated Children’s Hospital, Chongqing, China
This study was supported by the VIVA China Children’s Cancer
Foundation, and funded by Clinical Research Center of
Shandong University (No. 2020SDUCRCA010).
第一作者机构：[1]Department of Pediatrics, Qilu Hospital of Shandong University, Jinan, China,
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Zhuang Yong,Wu Kefei,Zhu Xiaofan,et al.Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children's Cancer Group.[J].FRONTIERS IN ONCOLOGY.2022,12:doi:10.3389/fonc.2022.911567.
APA：
Zhuang Yong,Wu Kefei,Zhu Xiaofan,Cai Jiaoyang,Hu Shaoyan...&Ju Xiuli.(2022).Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children's Cancer Group..FRONTIERS IN ONCOLOGY,12,
MLA：
Zhuang Yong,et al."Reduced Dose Intensity of Daunorubicin During Remission Induction for Low-Risk Patients With Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of the Chinese Children's Cancer Group.".FRONTIERS IN ONCOLOGY 12.(2022)
